The health authorities regulatory restriction of the prescription of anti-EGFR monoclonal antibodies to wild-type KRAS tumor patients plays a major role in selecting anti-VEGF or anti-EGFR introduction in first-line therapy. This evidence concerns the gene KRAS and neoplasm.